Systemic Enzyme Therapy in Prevention ofPostirradiation Complications
; J. Betka
*; J. Klozar
*; M. Taudy
*; M. Honzíková
Otorinolaryngologické oddělení VFN Praha, přednosta doc. MUDr. M. Hroboň, CSc. Klinika Otorinolaryngologie a chirurgie hlavy a krku 1. LF UK Praha, přednosta prof. MUDr. J. Betka, DrSc. *MUCOS Pharma CZ, s. r. o., Průhonice
Otorinolaryng. a Foniat. /Prague/, , 1999, No. 1, pp. 14-17.
The authors present their initial experience with the preparation Wobenzym asa radioprotective agent. Systemic enzyme therapy was administered to 10 patients with squamous-cell carcinoma of the oropharynx after buccopharyngotomy with mandibulotomy and osteosynthe-sis with subsequent postoperative radiotherapy. Before the beginning of the prospectiveinvestigation Wobenzym was administered to three patients after buccopharyngotomy and mandi-bulotomy with osteosynthesis and postirradiation osteoradionecrosis, together with Dalacin. Inpatients with postirradiation necrosis also laboratory examinations of urine were made to detectpyridinium cross bonds as a marker of impaired bone metabolism.Postirradiation mucosal and osseous changes were evaluated according to the WHO scale. In noneof the patients radiotherapy had to be discontinued on account of severe mucositis or dermatitis. In none of the patients of the group late postirradiation changes were detected such as osteoradionec-rosis. Administration of systemic enzyme therapy as a radioprotective procedure is evaluatedfavourably by the authors.
mandibulotomy, osteoradionecrosis, radioprotective agent, pyridinium cross bonds.
Full text is not available online.
If interested in a scan of this journal, contact NTO ČLS JEP